TherapeuticsMD, Inc.

239 articles with TherapeuticsMD, Inc.

• TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

  1/3/2023

  TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited.

• TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

  12/4/2022

  TherapeuticsMD, Inc. announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States.

• TherapeuticsMD Announces Third Quarter 2022 Financial Results

  11/14/2022

  TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2022.

• TherapeuticsMD Announces Additional $7 Million Private Placement

  10/31/2022

  TherapeuticsMD, Inc. announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP.

• TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

  9/12/2022

  TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers.

• TherapeuticsMD Announces Second Quarter 2022 Financial Results

  8/15/2022

  Quarterly total net revenue of $28.6 million ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 Conference call scheduled for 8:30 a.m. ET TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.

• TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

  8/8/2022

  TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.

• TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

  8/1/2022

  TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock from Rubric Capital Management LP.

• EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

  7/6/2022

  EW Healthcare Partners, has announced that Athene Merger, Inc., an affiliate of EW, has extended the expiration date of its tender offer to purchase all issued and outstanding shares of TherapeuticsMD, Inc., at a price of $10.00 per share until one minute after 11:59 PM, New York City time, on July 12, 2022, unless further extended in accordance with the terms of the Merger Agreement and the applicable rules and regulations of the SEC.

• 

  Money on the Move: Sapience Scores $41m Backed by BMS, NexPoint

  6/2/2022

  Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.

• TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

  5/20/2022

  TherapeuticsMD, Inc. today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA.

• TherapeuticsMD Announces First Quarter 2022 Financial Results

  5/16/2022

  TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the first quarter ended March 31, 2022.

• TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

  5/10/2022

  TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets.

• TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

  4/14/2022

  TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced the closing of the divestiture of vitaCare Prescription Services to GoodRx, in a cash transaction valued at $150 million, subject to a working capital adjustment.

• 

  FDA Action Alert: BMS, Marinus, Merck and More

  3/14/2022

  The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here's a look.

• TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

  3/10/2022

  TherapeuticsMD, Inc. today reported financial results for the fourth quarter ended December 31, 2021.

• U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

  12/10/2021

  TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company.

• TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

  12/8/2021

  TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”).

•  TherapeuticsMD Announces Third Quarter 2021 Financial Results

  11/11/2021

  TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2021.

• TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

  10/27/2021

  TherapeuticsMD, Inc. today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets.